More than a third of fibromyalgia patients are using CBD to help manage symptoms, according to a new survey in the US.
An estimated one-third of patients with fibromyalgia reported using cannabidiol for symptom management, according to survey data published this month.
Investigators at the University of Michigan Medical School surveyed over 2,700 patients – mostly from the United States – with a diagnosis of fibromyalgia about their use of CBD.
Thirty-two percent of respondents said they were current consumers of CBD, with consumers generally reporting turning to CBD because they had experienced inadequate relief from conventional medications.
The results, published in the Journal of Pain found that patients were most likely to report using CBD for pain management and anxiety, as well as for improving sleep.
The majority of consumers reported some degree of efficacy associated with CBD, with reporting “slight to much improvement across symptom domains”.
While two-thirds of participants disclosed their CBD use to their doctor, only 33 percent asked them for advice on using CBD.
Fibromyalgia is a chronic pain syndrome, characterised by widespread, severe musculoskeletal pain and fatigue.
It is the second most common rheumatological condition in the world, thought to affect five to seven per cent of the global population and predominantly women.
A number of studies have examined the efficacy of CBD and medical cannabis on fibromyalgia symptoms.
In a 2020 study of 102 patients, participants were prescribed two oil-diluted cannabis extracts and assessed periodically over six months, using standard fibromyalgia scoring techniques.
The use of the CBD was associated with a marked reduction of use of traditional painkillers; analgesic treatment was reduced or suspended in 47 per cent of the patients.
However, researchers at the University of Michigan Medical School concluded: “This article indicates that CBD use is common among people with fibromyalgia, and the results suggest that many derive benefit from using CBD across multiple symptoms domains.
“Clinicians should discuss CBD use with fibromyalgia patients, and future studies are needed to rigorously assess CBD’s therapeutic value for fibromyalgia symptoms.”
Full text of the study, “Cannabidiol use for fibromyalgia: Prevalence of use and perceptions of effectiveness in a large online survey,” appears in The Journal of Pain.
Australia lists first subsidised medical cannabis drug
Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.
The epilepsy drug, Epidyolex has become the first medical cannabis product to be subsidised by the Australian Government.
Australians living with the rare form of epilepsy known as Dravet syndrome, will now have access to the cannabis-derived drug via the country’s Pharmaceutical Benefits Scheme (PBS) for the first time.
As of 1 May, 2021, Epidyolex, which contains CBD, is listed on the PBS for patients with the treatment-resistant condition, to be used in combination with at least two other anti-epileptic medicines.
Epidyolex is only the second medicinal cannabis drug registered for supply in Australia, and the first one to be subsidised by the Government on the PBS.
Dravet syndrome is a rare, genetic epileptic encephalopathy that gives rise to seizures which don’t respond well to the standard medications.
It is estimated that around 116 patients each year will benefit from the listing of Epidyolex, who might otherwise pay more than $24,000 per year for the treatment.
They will now pay only $41.30 per script or $6.60 if they have a concession card.
But as prescriptions are not covered under the PBS, they remain costly compared to conventional medicines and out of reach for many.
In a statement announcing the listing of Epidyolex, Australian Health Minister Greg Hunt said the Government’s commitment to ensuring patients can access affordable medicines “remains rock solid”.
Experts to explore the role of medical cannabis in women’s health
A line-up of leading experts will discuss how cannabis medicines can play a vital role in women’s health.
Leading pain specialist, Dr Sally Ghazaleh will join a line-up of experts to discuss how cannabis medicines can play a vital role in women’s health.
The first of a four-part webinar series, taking place on Wednesday 12 May, will focus on the experience’s of women who have not felt supported by the current healthcare system – and how cannabis has helped them find relief from their conditions.
Dr Sally Ghazaleh, a pain specialist at Integro Medical Clinics, will join Sarah Higgins, clinical nurse specialist and women’s health lead at Cannabis Patient Advocacy Support Services (CPASS), alongside endometriosis patients Abby Hughes, outreach chair of PLEA (Patient-Led Engagement for Access) and Laura, author of The Endomonologues blog.
Aimed at patients, clinicians and the general public the webinar series, hosted by Cannabis Health, Integro Clinics and CPASS, aims to discuss the application of cannabis medicines in the management of complex female health conditions.
It will also highlight some of the wider issues and gender inequalities played out in the modern medical model.
Studies have shown that women’s pain is not acted on as quickly and is more likely to be dismissed than men’s, while many conditions can present differently in women than in men and therefore take longer to diagnose.
Many women are still unaware of female-specific health conditions such as pelvic inflammatory syndrome (PIS) or vulvodynia and can live with the symptoms for many years before they are correctly diagnosed and treated.
Some patients are now reporting that they have found cannabis medicines to be helpful in the management of their health conditions.
Dr Ghazaleh, a consultant at Whittington Hospital and the National Hospital of Neurology and Neurosurgery in London, joined Integro Clinics as a prescriber of medical cannabis in January.
She specialises in managing patients with a wide range of pain conditions and has a particular interest in bladder and abdominal pain in women, and women’s health in general.
The free webinar will take place on Wednesday 12 May at 7pm.
The event is hosted by Cannabis Health, Integro Medical Clinics and CPASS, sign up for free here
If you would like further information, or to make an appointment for a medical consultation with Dr Sally Ghazaleh please contact Integro Clinics:
Cannabis treatment to be trialled for common pet health issue
Trials of a synthetic cannabinoid treatment for common eye problems in dogs have been given the green light.
Trials of a cannabis-derived treatment which could rid dogs of common and potentially blinding eye ulcers, have been given the go-ahead.
Tetra Bio-Pharma will continue with clinical trials on its synthetic cannabinoid products in the hope of finding an easy-to-use medication for pets with the painful condition.
Eye ulcers are one of the most common health problems in dogs and, if left untreated, can lead to the loss of an eye.
The condition is particularly common among a number of breeds which have gained in popularity in recents years, including pugs, bulldogs and West Highland terriers.
Initial symptoms include a red and aggravated eye and the condition often needs to be treated by a vet.
Progress has been slowed due to the Covid-19 pandemic but now the company is looking to forge ahead with the first-of-its-kind trial after receiving authorisation from the Veterinary Drugs Directorate of Health Canada.
The company is also engage in developing a treatment for acute respiratory distress syndrome (ARDS) which could eventually be used to treat people suffering with the coronavirus.
The trials of PPP-003v, Tetra’s proprietary veterinary ocular formulation for treating ocular pain and inflammation in companion animals, could see Tetra find a way into a market expect to be worth over $220 million by 2026.
Dr Guy Chamberland, CEO and CRO of Tetra Bio-Pharma, said: “The PPP-003 program, including PPP-003v, represents a significant opportunity for Tetra since there is a substantial unmet medical need for painful inflammatory eye disease.”
He added: “We are pleased with this regulatory authorisation and the ability to re-activate the trial.
“While the active pharmaceutical ingredient used in the PPP-003v drug formulation is the same as the one used in ARDS-003, Tetra’s innovative immunomodulator drug concurrently being developed for Covid-19, there is a major difference with how the drug is delivered.
“PPP-003v is intended to be used as a topical medication and is delivered as a sterile eye drop and ointment, while ARDS-003 is a sterile injectable nano-emulsion finished drug product.”
Introducing our new B2B title
- Tackling adult acne with the help of CBD
- Australia lists first subsidised medical cannabis drug
- Experts to explore the role of medical cannabis in women’s health
- Cannabis treatment to be trialled for common pet health issue
- Why more people turned to cannabis during the pandemic
- The Jiu Jitsu enthusiast tackling CBD stigma in black and Asian communities
News10 months ago
NHS lines up cannabis medicine manufacturing
News6 months ago
Community extends support to cannabis icon Rick Simpson
Case Studies1 year ago
CBD oil and fibromyalgia – a case study
Feature11 months ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Insight7 months ago
I’ve gone from a wheelchair to walking thanks to cannabis
News8 months ago
Cancer survivor claims cannabis oil helped her beat brain tumour
Industry4 months ago
“Game changer” for the sector: First cannabis company expected to list on LSE next month
News8 months ago
“I’m not a bad person” – chronically ill woman convicted of growing medical cannabis